Guest guest Posted July 7, 2010 Report Share Posted July 7, 2010 While there are many new and exciting treatments in the pipelines, like CAL-101, RO5072759, BCL-2 uptake inhibitors, CD19 mAbs and perhaps siRNAs the problem of B-cell differentiation remains illusive. If we had a method of targeting good B-cells from malignant B-cells and only killing the malignant cells, then CLL would largely be a controllable cancer. All current approved treatments wipe out large portions of the immune system. They take out ALL B-cells and some also have a detrimental effect on the T-cell population. While these cell populations return to some extent they never reach their pre-treatment levels. Some look to HSCT, and it is been touted recently in the press as a CLL treatment option. However, it has a less than 50% chance of working and should only be considered for patients who have run out of options and that are at an age (usually under 60 years) and level of health to withstand having their immune systems totally wiped out and replaced with the immune system of a matched donor. But even in the best transplant situation CLL will return. It is not a cure... ~chris http://cllcanada.ca Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.